PUMA
4.11.2021 10:02:19 CET | Business Wire | Press release
Sports company PUMA has developed an experimental version of its most iconic sneaker, the SUEDE, to test for a product to make it biodegradable. By doing so, PUMA aims to meet the growing demand for sustainable products for a better future. The RE:SUEDE, which uses the latest technology available today, will be made from more sustainable materials such as Zeology tanned suede, biodegradable TPE and hemp fibres.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005105/en/
The RE:SUEDE experiment is a pilot in circularity, and today’s ultimate expression of the next generation SUEDE – with the ambition to set new standards of sustainability for the iconic shoe. Designed to help address the challenge of waste management in the footwear industry, the RE:SUEDE experiment will allow PUMA to take more responsibility when it comes to tackling the ‘after life’ of its products. The pilot will launch in January 2022, offering 500 selected participants in Germany the chance to join PUMA on its experimental journey towards circularity.
In partnership with PUMA, participants will wear their RE:SUEDEs for six months to test out the durability of a product using biodegradable materials in real life, before sending them back to PUMA via a take back infrastructure, designed to move the products to the next step in the experiment. The sneakers will then be subject to an industrial biodegradation process in a controlled environment at Valor Compostering B.V., owned by Ortessa Groep B.V., a family-run business of waste specialists in the Netherlands. The goal of this step is to determine if Grade A compost can be produced for agricultural use. The findings will help PUMA assess the biodegradable process and unpick essential research and development for the future of sustainable shoe consumption.
The RE:SUEDE experiment is the first circular programme to launch under PUMA’s “Circular Lab” – a new innovation hub, which is led by PUMA’s sustainability and design experts who work to develop the future of the company’s circularity programmes.
This pilot is a recharged, refreshed experiment in circularity, following PUMA’s exploration in the space in 2012, which saw the brand’s first attempt to create a biodegradable sneaker as part of its InCycle collection. Yet after four seasons, the sneaker was discontinued due to low demand and the need for further research and development.
Since 2012, PUMA’s innovation department has worked to address the technological limitations of the InCycle collection in order to apply such learnings into the RE:SUEDE experiment. Improvements include the use of new, innovative materials such as Zeology suede, which is made using a more sustainable tanning process and ensures better comfort for the wearer, when compared to other biodegradable materials evaluated at PUMA. The outsole of the RE:SUEDE has also been improved to ensure optimal wear.
“In 2012, our circular ambition was bold but the technology wasn’t quite there. As they say, with every challenge there’s an opportunity - and we’ve continued to push ourselves to do better by applying our strengths as well as acknowledging and improving on our weaknesses,” said Heiko Desens, PUMA’s Creative Director. “We hope that progress made during the RE:SUEDE experiment: ‘No Time For Waste‘ will help us continue to raise the bar in circularity testing – enabling our consumers to make better fashion choices in the future, so their sneakers can go ‘from Suede to Soil’, without compromising on product style or durability during ownership.”
About the partnership with Ortessa, Desens further comments: “We’re excited to partner with the experts at Ortessa, who share our passion in developing proactive and pragmatic solutions to the industry‘s waste problem. Their expertise is fundamental in helping us learn more about the after life of the RE:SUEDE, so we can continue moving forwards on our exploration of circularity.“
Rob Meulendijks, CEO of Ortessa comments: “As a family owned challenger in the waste industry, we pride ourselves in creating surprising innovations and fresh concepts to tackle real waste issues in a different and open way. There is a lot more we can all be doing to help tackle waste management, but taking on that challenge alone can be a difficult task for any brand. We are delighted to be working in partnership with PUMA on this special project, where we can apply our deep knowledge and insights on waste, use tried and controlled methods, to assess the biodegradability of the future, next-generation Suede.“
PUMA aims to share the results and insights gained from this experiment within the industry to achieve an even bigger impact when it comes to addressing the challenge of waste management in the footwear industry in general. Circularity is one of the pillars of PUMA’s FOREVER BETTER sustainability strategy. By 2025, PUMA aims to reduce waste by increasing the level of recycled polyester in its products to 75%, setting up product takeback schemes in its major markets and developing recycled material options for leather, rubber, cotton and polyurethane.
Since its first iteration in 1968, the PUMA SUEDE has been at the forefront of cultural turning points, transcending style and trends. With the RE:SUEDE, PUMA wants to give its consumers a stylish and more sustainable choice, while showcasing the latest technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005105/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
